Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I clinical trials for cardiovascular diseases in Europe: analysis of trends, distribution, and regulatory context.

Frontiers in pharmacology·2026
Same author

Mechanical load inhibits cancer growth in mouse and human hearts.

Science (New York, N.Y.)·2026
Same author

Cancer prevention and cancer avoidance: Challenges and opportunities.

Tumori·2026
Same author

Stereotactic radioablation for ventricular tachycardia in patients untreatable by catheter ablation: evidence of efficacy, safety, and impact on coronary arteries.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Epigenetic Drugs Splitomicin, Suberohydroxamic Acid, CPTH6, BVT-948, and PBIT Moderate Fibro-Fatty Development in Arrhythmogenic Cardiomyopathy.

Biomolecules·2025
Same author

Percentage of left ventricular myocardial blood flow distribution and revascularization completeness in FASTTRACK CABG.

Journal of cardiovascular computed tomography·2025

Related Experiment Video

Updated: May 23, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

MicroRNAs and myocardial infarction.

Yuri D'Alessandra1, Giulio Pompilio, Maurizio C Capogrossi

  • 1Laboratorio di Biologia Vascolare e Medicina Rigenerativa, Centro Cardiologico Monzino - IRCCS, Milan, Italy.

Current Opinion in Cardiology
|April 6, 2012
PubMed
Summary

MicroRNAs (miRNAs) are significantly altered in myocardial infarction (MI), impacting cardiac repair and complications. These small noncoding RNAs show promise as novel biomarkers and therapeutic targets for MI treatment.

More Related Videos

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Related Experiment Videos

Last Updated: May 23, 2026

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease
04:41

Digital PCR for Quantifying Circulating MicroRNAs in Acute Myocardial Infarction and Cardiovascular Disease

Published on: July 3, 2018

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge
09:53

In Vivo Nanovector Delivery of a Heart-specific MicroRNA-sponge

Published on: June 15, 2018

Area of Science:

  • Cardiovascular Biology
  • Molecular Biology
  • Biochemistry

Background:

  • MicroRNAs (miRNAs) are small noncoding RNAs that regulate gene expression.
  • Myocardial infarction (MI) is a critical condition involving heart muscle damage.
  • Dysregulation of miRNAs is increasingly implicated in cardiovascular diseases.

Purpose of the Study:

  • To review the role of miRNAs in myocardial infarction (MI).
  • To examine miRNA expression changes in the heart and circulation post-MI.
  • To identify miRNAs with therapeutic potential and those modulated by MI therapies.

Main Methods:

  • Literature review of studies on miRNAs in MI.
  • Analysis of miRNA expression profiles in cardiac and circulating samples.
  • Evaluation of therapeutic strategies targeting miRNAs in MI models.

Main Results:

  • Cardiac and circulating miRNA levels are significantly altered in MI.
  • Altered miRNAs provide insights into MI complications, ventricular remodeling, and repair.
  • Circulating miRNAs show potential as sensitive MI biomarkers and intercellular signaling molecules.
  • miRNA overexpression or downregulation is being explored for MI treatment.
  • Existing and experimental MI therapies may exert effects through miRNA modulation.

Conclusions:

  • The role of miRNAs in MI is still under investigation but is rapidly evolving.
  • miRNAs represent promising novel therapeutic targets for MI.
  • miRNAs are emerging as valuable biomarkers for diagnosing and monitoring MI.